Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study

BACKGROUND: CT-P13 (Remsima®, Inflectra®) is a biosimilar of the infliximab reference product (RP; Remicade®) and is approved in Europe and elsewhere, mostly for the same indications as RP. The aim of this study was to compare the 54-week efficacy, immunogenicity, pharmacokinetics (PK) and safety of...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Won, Yoo, Dae Hyun, Jaworski, Janusz, Brzezicki, Jan, Gnylorybov, Andriy, Kadinov, Vladimir, Sariego, Irmgadt Goecke, Abud-Mendoza, Carlos, Escalante, William Jose Otero, Kang, Seong Wook, Andersone, Daina, Blanco, Francisco, Hong, Seung Suh, Lee, Sun Hee, Braun, Jürgen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4721187/
https://www.ncbi.nlm.nih.gov/pubmed/26795209
http://dx.doi.org/10.1186/s13075-016-0930-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4721187/
https://www.ncbi.nlm.nih.gov/pubmed/26795209
http://dx.doi.org/10.1186/s13075-016-0930-4

Ejemplares similares